

## Press Release

**Contact:** Cameron Macdonald  
Managing Director  
Controlled Therapeutics (Scotland) Ltd  
1 Redwood Place, Peel Park Campus  
East Kilbride G74 5PB  
01355 239166

### **Controlled Therapeutics Collaborates with CONRAD to Develop Vaginal Ring for Prevention of HIV Infection**

**East Kilbride, Scotland, February 1, 2010.** Controlled Therapeutics (Scotland) Ltd (CTS) today announced that it has initiated a development programme in partnership with CONRAD, a USA based not-for-profit product development organization. The programme will assess whether CTS' new polymer drug delivery system can be used in the form of a vaginal ring to deliver effective doses of microbicides for periods of up to three months, the aim being to prevent the transmission of HIV and other viral infections.

The project, which started in December 2009, will be reviewed after one year to assess progress before further commitments are made.

"We see this as an exciting opportunity to demonstrate the effectiveness of our drug delivery technologies in a demanding clinical situation," said Cameron Macdonald, Ph.D., Managing Director at CTS. "We are also delighted to be working with an organization like CONRAD with its commitment to improving the health and welfare of women across the world."

A number of microbicides in the form of gels, creams or films, are currently in development for the prevention of HIV infection. These are inserted in the vagina before intercourse. Several organizations are also conducting clinical trials to test the efficacy of antiretroviral pills against HIV infection. If vaginal rings containing microbicides prove effective in preventing HIV infection, they will provide women with protection that doesn't rely on a daily action, such as taking a pill, or inserting a gel or cream, or taking pre coital action. "We strongly believe that women should be empowered to protect themselves against HIV infection and that women should have a variety of methods to do so, just as they do with birth control. We hope this collaboration with Controlled Therapeutics moves the field forward and will eventually provide women with a favorable option," said Henry Gabelnick, Executive Director of CONRAD.

#### **About CTS**

CTS is a wholly owned subsidiary of [Cytokine PharmaSciences Inc.](#) (CPSI), a Delaware corporation having its principal place of business in the United States at King of Prussia,

Pennsylvania. CPSI is engaged in developing anti-inflammatory and autoimmune therapeutics.

CTS develops and manufactures controlled release drug delivery products targeted in the area of women's health. Its cervical ripening product, which sells under the brand name Cervidil® in the USA and Propess® elsewhere, is now marketed in over 40 countries. The company has a further two controlled release products in clinical development and one in pre-clinical development.

For further information, please visit the Company's websites at [www.ctscotland.com](http://www.ctscotland.com) and [www.cytokinepharmacsciences.com](http://www.cytokinepharmacsciences.com).

### **About CONRAD**

CONRAD is a cooperating agency of USAID committed to improving reproductive health by expanding the contraceptive choices of women and men and by helping to prevent the transmission of HIV/AIDS and other sexually transmitted diseases. CONRAD is a Division of the Department of Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in Norfolk, VA, where it has laboratories and a clinical research center. The main office is located in Arlington, VA with additional offices in Atlanta, GA and West Chester, PA.

Partnerships with a variety of for-profit entities for specific projects have been established, including, Personal Products (J&J), Polydex, ReProtect, Biosyn, Schering AG (now Bayer Schering Pharma), Laboratorios Silesia (now part of Andromaco Group), Gedeon Richter, Aplicaciones Farmaceuticas, and Integra LifeSciences.

For further information on CONRAD, please visit its website at [www.conrad.org](http://www.conrad.org).